Gut-brain axis in Alzheimer's disease: neuroinflammatory mechanisms and immunopharmacological interventions. (PubMed, Inflammopharmacology) - Oct 25, 2026 - "Despite being defined pathologically by amyloid-β plaques, chronic neuroinflammation and neurofibrillary tangles, the drugs that target these processes directly (lecanemab and donanemab) have only modest effects on the clinical course of Alzheimer's disease (AD) and significant safety concerns have been identified, so there is renewed interest in upstream, systemic contributors to disease...Then we review the immunopharmacological interventions intended to break this axis - probiotic supplementation (some consistent benefit - although mild) and sodium oligomannate, with strong preclinical and case report signals that need human trials (in 2026) and polyphenols and GLP-1 receptor agonists, which have a persistent disconnect between mechanistic promise and clinical efficacy, including a definitive null result for semaglutide in 2026. Translative directions are addressed to nanotechnology-based delivery systems for improving bioavailability and blood-brain..."
Journal • Review • Alzheimer's Disease • CNS Disorders • Gastrointestinal Disorder • Inflammation • NLRP3 • TLR4
|
|
Abhay Thakur; Gaurav Kumar; Rishab Sharma
|